Peptides for Cardiovascular Research: Vasodilatory, Cardioprotective & Metabolic Compounds Ranked

Peptides studied in cardiovascular research span three mechanistic categories: vasodilatory neuropeptides that relax vascular smooth muscle, mitochondria-targeted antioxidants that protect cardiomyocytes from oxidative injury, and incretin-axis agonists whose cardiac outcome data now spans three large published trials. This ranked overview covers 7 compounds that have appeared in cardiovascular-relevant preclinical or clinical literature, organized by depth of available evidence as of 2026. It is intended as a research reference for scientists and clinicians studying these pathways.

Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.

Quick Answer: Semaglutide and SS-31 (elamipretide) represent the two most evidence-rich peptides in cardiovascular research by evidence tier — semaglutide through 3 cardiovascular outcomes trials including SELECT (20% MACE reduction in non-diabetic individuals with obesity), and SS-31 through direct mitochondrial cardioprotection now under Phase 3 investigation in heart failure with preserved ejection fraction.

How we ranked

Compounds are ordered by four criteria applied in sequence: (1) regulatory maturity and clinical evidence tier (Phase 3 ≥ Phase 3 CVOT > Phase 2 > preclinical only), (2) mechanistic specificity to cardiovascular endpoints versus intermediary metabolic effects, (3) breadth of published cardiovascular literature in PubMed, and (4) how frequently the compound appears in cardiovascular-focused preclinical model protocols. Compounds at equivalent evidence tiers are ranked by mechanistic specificity to cardiac outcomes. All compounds are covered in research framing only; no dosing guidance is included or implied.

1. Semaglutide: GLP-1 agonist with three published cardiovascular outcomes trials

Semaglutide is a GLP-1 receptor agonist with the deepest cardiovascular clinical trial evidence base of any peptide in this review. GLP-1 receptors are expressed in cardiomyocytes, sinoatrial node tissue, coronary endothelium, and the nucleus tractus solitarius — receptor distribution that explains the compound's pleiotropic cardiovascular effects beyond glucose and weight regulation. GLP-1R activation elevates intracellular cAMP and activates downstream PKA signaling, reducing oxidative stress, attenuating ischemia-reperfusion injury markers, and modulating NF-κB-dependent inflammatory cytokine cascades in cardiac tissue.

Three major outcomes trials define semaglutide's cardiovascular evidence base. SUSTAIN-6 (Marso et al., NEJM 2016) demonstrated a 26% reduction in major adverse cardiovascular events (MACE) versus placebo in patients with type 2 diabetes and high cardiovascular risk. PIONEER-6 confirmed cardiovascular safety for the oral semaglutide formulation. The SELECT trial (2023) is the most significant: it documented a 20% reduction in MACE in individuals without diabetes who had preexisting cardiovascular disease and obesity — the first such cardiovascular outcome demonstrated in a non-diabetic obesity population using any pharmacological agent.

Research applications for semaglutide in cardiovascular contexts include GLP-1R-dependent cardioprotective signaling in isolated cardiomyocytes, ischemic preconditioning mechanism studies, and cardiac inflammatory pathway modulation in metabolic syndrome models. Regulatory status: FDA-approved (Ozempic for T2D; Wegovy for obesity). The active peptide sequence is a component of an FDA-approved drug product.

Internal link: Semaglutide research profile

PMID 42027588 | DOI: https://doi.org/10.1056/NEJMoa1607141

2. Tirzepatide: Dual GIP/GLP-1 agonist with cardio-metabolic-kidney outcome data

Tirzepatide is a 39-amino acid dual agonist targeting both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP receptor co-activation in adipose tissue and cardiomyocytes adds a mechanistically distinct signaling layer: GIP receptor engagement recruits cAMP/PKA signaling through a separate receptor subtype, producing additive effects on lipid oxidation, hepatic fat clearance, and adipose insulin sensitivity that complement GLP-1R-mediated cardiac effects.

Real-world evidence published in 2026 from a single-center cohort of 100 adults with obesity demonstrated that long-term tirzepatide use (>1 year) produced clinically meaningful cardiometabolic improvements: LDL-cholesterol decreased 30.5%, triglycerides decreased 32.5%, and eGFR improved 3.2% — effects substantially greater than in the short-term (<1 year) cohort. Hepatic enzymes SGOT and SGPT declined significantly only in the long-term group, indicating progressive reversal of hepatic steatosis with sustained treatment. The SURPASS-CVOT trial is specifically designed to evaluate cardiovascular outcomes in type 2 diabetes with tirzepatide versus placebo.

For cardiovascular researchers, tirzepatide is particularly useful in studying how dual incretin receptor co-stimulation affects lipotoxic cardiomyopathy models, cardiac metabolic flexibility under dual cAMP stimulation, and renal-cardiac crosstalk in obesity-related heart disease. Regulatory status: FDA-approved (Zepbound for obesity; Mounjaro for T2D). Active peptide compounding regulations apply as for semaglutide.

Internal link: Tirzepatide research profile

PMID 42029986 | DOI: https://doi.org/10.1056/NEJMoa2107519

3. SS-31: Mitochondria-targeted peptide under Phase 3 evaluation in heart failure

SS-31 (elamipretide; Szeto-Schiller peptide 31) is a tetrapeptide (D-Arg-Dmt-Lys-Phe-NH₂) rationally designed to selectively accumulate in the inner mitochondrial membrane via electrostatic interaction with cardiolipin — the phospholipid essential for maintaining electron transport chain complex stability and cristae architecture. Under oxidative stress, hydrogen peroxide accumulation oxidizes cardiolipin, triggering membrane potential collapse and downstream cardiomyocyte apoptosis. SS-31 scavenges H₂O₂ at this specific inner membrane location and prevents cardiolipin oxidation, preserving mitochondrial integrity at the upstream chokepoint of cardiomyocyte death signaling.

Preclinical work using rat cardiomyocyte H9c2 cells with peroxiredoxin III (PrxIII) knockdown demonstrated that >10-fold H₂O₂ accumulation causes impaired mitochondrial fusion, disrupted autophagic flux, and enhanced apoptosis — all rescued by SS-31 administration, which restored mitophagy efficiency and preserved autophagic flux at levels comparable to moderate H₂O₂ exposure in PrxIII-expressing controls. In vivo experiments using PrxIII knockout mice confirmed that SS-31 prevents exacerbated cardiac dysfunction without affecting systemic fibrosis or hypertrophy, indicating targeted mitochondrial-specific rescue rather than systemic suppression.

Phase 2 data (Szeto et al., JACC 2018) demonstrated improved cardiac energetics in heart failure patients with preserved ejection fraction (HFpEF) — a condition characterized mechanistically by mitochondrial dysfunction and impaired myocardial energetics. The PROGRESS-HF Phase 3 trial currently evaluates elamipretide in HFpEF, making SS-31 the most clinically advanced mitochondria-targeted peptide in cardiovascular development. Regulatory status: investigational (Phase 3); 503A status under review.

Internal link: SS-31 compound profile

PMID 42013545 | DOI: https://doi.org/10.1089/ars.2012.4849

4. VIP: Vasodilatory neuropeptide with Phase 2 pulmonary hypertension data

Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide that acts on VPAC1 and VPAC2 G-protein-coupled receptors expressed in vascular smooth muscle, cardiomyocytes, and immune cells throughout the pulmonary and systemic vasculature. VPAC receptor activation stimulates adenylyl cyclase via Gs coupling, elevating intracellular cAMP and triggering protein kinase A-mediated phosphorylation of myosin light chain kinase — producing potent, receptor-specific vasodilation without the nonspecific receptor profile of nitric oxide donors.

Beyond vasodilation, VIP suppresses NF-κB-dependent cytokine production (TNF-α, IL-6, IL-12) and promotes regulatory T-cell differentiation — a dual vasodilatory-immunomodulatory profile with relevance to atherosclerosis, inflammatory cardiomyopathy, and pulmonary arterial hypertension (PAH) research. In preclinical PAH models, inhaled VIP reduced mean pulmonary arterial pressure by 15–30%. A Phase 2 randomized trial published in NEJM (Petkov et al., 2003) documented improvements in 6-minute walk distance and hemodynamic parameters with inhaled VIP in PAH patients, though the compound has not advanced to Phase 3.

Researchers studying vascular tone regulation, pulmonary endothelial function, or inflammatory cardiomyopathy have included VIP in preclinical protocols due to its selective VPAC receptor mechanism and the availability of well-characterized receptor subtypes for experimental manipulation. Regulatory status: investigational (Phase 2); 503A status under review.

Internal link: VIP compound profile

PMID 42027914 | DOI: https://doi.org/10.1042/BST0331114

5. MOTS-c: Mitochondria-derived metabolic regulator in cardiac aging research

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino acid peptide encoded within the mitochondrial genome — specifically within the 12S rRNA gene — making it part of a class of mitochondria-derived peptides (MDPs) that communicate metabolic state from mitochondria to the nucleus and peripheral tissues. Its primary signaling mechanism involves activation of AMPK (AMP-activated protein kinase), the master regulator of cellular energy homeostasis, which downstream promotes glucose uptake, fatty acid oxidation, and mitochondrial biogenesis.

Foundational work by Lee et al. (Cell Metabolism, 2015) demonstrated that MOTS-c administration in rodents improved insulin sensitivity, activated AMPK in skeletal muscle and adipose tissue, and prevented diet-induced obesity. Human plasma MOTS-c levels decline with age, correlating with the age-dependent deterioration in cardiac metabolic flexibility — the ability to switch efficiently between glucose and fatty acid substrates — that characterizes early cardiometabolic dysfunction. In aged rodent models, exogenous MOTS-c improved exercise capacity and insulin sensitivity markers relevant to metabolic syndrome-driven cardiovascular risk.

Cardiac-specific research applications include studying MOTS-c's role in AMPK-mTORC1 signaling under ischemic metabolic stress, its interaction with the mitochondrial unfolded protein response in aged cardiac tissue, and its potential to modulate substrate utilization in cardiomyocytes under metabolic-stress conditions. Regulatory status: preclinical; 503A status under review.

Internal link: MOTS-c compound profile

PMID 41945630 | DOI: https://doi.org/10.1016/j.cmet.2015.01.013

6. Humanin: Cytoprotective mitochondrial peptide in cardiomyocyte apoptosis models

Humanin is a 21-amino acid peptide encoded within a mitochondrial open reading frame in the 16S rRNA region, first identified in 2001 from neurons of Alzheimer's disease patients surviving neurodegeneration. Its cytoprotective mechanism involves binding to a heteromeric receptor complex composed of FPRL1 (formyl peptide receptor-like 1) and IL-6Rα, activating JAK-STAT3 and PI3K/Akt survival signaling cascades that suppress pro-apoptotic BAD and caspase-3 activity while upregulating Bcl-2 expression. Within mitochondria directly, humanin stabilizes cytochrome c against release and reduces reactive oxygen species production under oxidative challenge.

In cardiomyocyte models, humanin has been studied as a survival-promoting agent under ischemia-reperfusion conditions. Preclinical data published in PNAS and Nature Medicine demonstrate protection against myocardial ischemia-reperfusion injury in rodent models — humanin administration before reperfusion significantly reduced infarct size and apoptosis markers compared to control conditions. Human plasma humanin levels decline with age, and several observational studies have associated lower circulating humanin concentrations with increased cardiovascular risk markers and worse metabolic profiles in older adults.

As a mitochondrial peptide, humanin occupies a complementary niche to SS-31: SS-31 acts at the cardiolipin/H₂O₂ interface in the inner membrane, while humanin operates through receptor-mediated apoptosis suppression and intramitochondrial ROS reduction. Researchers studying the interplay of these pathways in aged or ischemic cardiac tissue may find both compounds relevant to the same experimental model. Regulatory status: preclinical; 503A status under review.

Internal link: Humanin compound profile

PMID 41975304 | DOI: https://doi.org/10.1073/pnas.101208398

7. Hexarelin: GHRP with GHS-R-independent cardiac binding

Hexarelin (examorelin) is a synthetic hexapeptide growth hormone secretagogue whose cardiovascular relevance stems from a receptor mechanism that is entirely independent of pituitary GH release. Research by Torsello et al. (European Journal of Pharmacology, 2002) identified a non-GHS-R1a binding site in cardiac tissue through which hexarelin exerts cardioprotective effects — mechanistically separating its pituitary actions from its direct cardiac actions and allowing study of cardiac peptide receptors outside the GH axis.

Preclinical studies in rodent heart failure models demonstrated that hexarelin administration improved ventricular ejection fraction, reduced cardiomyocyte hypertrophy markers, and attenuated cardiac fibrosis — effects observed at doses insufficient to produce significant GH stimulation, supporting the GHS-R-independent mechanism. Additional data in doxorubicin cardiotoxicity models found hexarelin preserved cardiac structure and function compared to control animals. In isolated rat cardiomyocytes, hexarelin activated PI3K/Akt and ERK1/2 survival pathways that do not require GHS-R1a engagement.

Unlike ipamorelin — which is highly selective for GHS-R1a with minimal cortisol or ACTH co-stimulation — hexarelin stimulates the hypothalamic-pituitary-adrenal axis (cortisol and ACTH elevation) alongside GH, a selectivity difference relevant to experimental design in stress-sensitive cardiac models. WADA-prohibited substance (S2 category). Regulatory status: discontinued as a therapeutic compound; 503A status under review.

Internal link: Hexarelin compound profile

PMID 40465419 | DOI: https://doi.org/10.1210/jcem.84.6.5815

Comparison table

Compound	Mechanism	Regulatory status	Cardiovascular evidence tier	Primary CV research application
Semaglutide	GLP-1 receptor agonist	FDA approved	3 CVOTs (SUSTAIN-6, PIONEER-6, SELECT)	GLP-1R cardioprotective signaling; MACE outcomes
Tirzepatide	Dual GLP-1/GIP agonist	FDA approved	SURPASS-CVOT (ongoing)	Dual incretin cardio-metabolic research; lipotoxicity
SS-31	Cardiolipin protector (inner mitochondrial membrane)	Phase 3 investigational	Phase 3 PROGRESS-HF	Mitochondrial quality control; HFpEF research
VIP	VPAC1/VPAC2 receptor agonist	Phase 2 investigational	Phase 2 PAH (Petkov NEJM 2003)	Pulmonary vasodilation; vascular inflammation
MOTS-c	AMPK activator (mitochondrial origin)	Preclinical	Preclinical aged rodent models	Cardiac metabolic aging; AMPK-mTORC1 axis
Humanin	JAK-STAT3/PI3K-Akt cytoprotector	Preclinical	Preclinical ischemia-reperfusion models	Cardiomyocyte apoptosis; ischemia-reperfusion
Hexarelin	GHS-R-independent cardiac receptor + GHS-R1a	Discontinued	Preclinical heart failure models	Cardiac fibrosis; GHS-R-independent signaling

Researchers planning cardiovascular peptide protocols can use the Peptide Reconstitution Calculator to calculate preparation volumes and target concentrations for in vitro or in vivo preclinical applications. For context on related immune-modulating research, the Peptides for Inflammation Research overview covers VIP's anti-inflammatory mechanism alongside other immunomodulatory compounds.

Regulatory note (2026): VIP, MOTS-c, SS-31, and hexarelin are among the compounds whose 503A bulk drug substance status is under review by the FDA Pharmacy Compounding Advisory Committee at its July 23–24, 2026 hearing. The regulatory outcome affects compounding pharmacy access but does not affect their investigational research status in preclinical or IND-approved clinical trial settings.

Frequently asked questions

Q: Which peptide has the most human cardiovascular trial data?

A: Semaglutide has the largest cardiovascular clinical trial evidence base among peptides, with three completed cardiovascular outcomes trials: SUSTAIN-6, PIONEER-6, and SELECT. The SELECT trial is particularly significant — it demonstrated a 20% reduction in MACE in individuals with obesity but without type 2 diabetes, marking the first such outcome documented in a non-diabetic obesity population using any pharmacological agent.

Q: What is SS-31 and how does it protect the heart in preclinical models?

A: SS-31 (elamipretide) is a tetrapeptide that selectively accumulates in the inner mitochondrial membrane, where it scavenges hydrogen peroxide and prevents cardiolipin oxidation — a proximal trigger for cardiomyocyte apoptosis. Preclinical studies in doxorubicin cardiotoxicity models and Phase 2 data in heart failure with preserved ejection fraction (HFpEF) support its cardioprotective mechanism, which operates through mitochondrial quality control restoration rather than receptor signaling.

Q: Is VIP relevant to pulmonary hypertension research?

A: Vasoactive Intestinal Peptide (VIP) has been studied in pulmonary arterial hypertension (PAH) preclinical models and a Phase 2 trial (Petkov et al., NEJM 2003) due to its potent VPAC1/VPAC2-mediated vasodilation and secondary NF-κB inhibitory effects on pulmonary vascular inflammation. The compound has not progressed to Phase 3 as a therapeutic, but its defined receptor pharmacology makes it useful for mechanistic pulmonary vascular research.

Q: How do MOTS-c and humanin differ in cardiovascular research contexts?

A: MOTS-c acts through AMPK pathway activation to improve glucose utilization and cardiac metabolic flexibility, targeting the metabolic substrate dysfunction that underlies cardiometabolic disease. Humanin activates JAK-STAT3 and PI3K/Akt cytoprotective signaling cascades to prevent cardiomyocyte apoptosis under ischemic or oxidative stress — a more direct anti-apoptotic mechanism suited to ischemia-reperfusion injury models rather than metabolic disease contexts.

Q: What makes hexarelin's cardiac mechanism distinct from other GHRPs?

A: Hexarelin binds a GHS-R-independent receptor in cardiac tissue that mediates cardioprotective effects without requiring GH release. Torsello et al. (2002) demonstrated improved ventricular function and reduced cardiac fibrosis at sub-GH-stimulating hexarelin doses, establishing that its cardiac effects are receptor-mechanistically distinct from the pituitary GHS-R1a agonism shared by all GHRPs. This makes hexarelin uniquely useful for studying cardiac peptide receptors outside the GH axis, despite its non-selective cortisol/ACTH co-stimulation.

Q: What is the difference between cardioprotective peptides that target mitochondria versus GLP-1 receptors?

A: Mitochondria-targeted peptides (SS-31, humanin, MOTS-c) protect cardiomyocytes at the level of cellular energy machinery — reducing ROS, preventing apoptosis, and maintaining ATP synthesis capacity. GLP-1/GIP receptor agonists (semaglutide, tirzepatide) work primarily through systemic metabolic improvement — reducing lipotoxicity, improving insulin sensitivity, and attenuating the chronic inflammatory state that drives atherosclerosis and cardiac remodeling over years. The two categories address different phases of cardiovascular pathophysiology and are not mechanistically interchangeable in research design.

See also:

• Tirzepatide Mechanism of Action: Dual GIP/GLP-1 Agonism in Research — detailed pharmacology of tirzepatide's dual incretin receptor signaling and SURPASS clinical data
• NAD+, MOTS-c, and Humanin: The Mitochondrial Peptide Cluster — broader mitochondrial signaling context for MOTS-c and humanin
• Peptides for Inflammation Research: 8 Compounds in Preclinical Studies — covers VIP's anti-inflammatory NF-κB mechanism alongside 7 other immunomodulatory compounds

Cited studies

• PMID 42027588 — "Unexplained hypercapnia with normal pulmonary evaluation in a patient receiving semaglutide: a diagnostic challenge." (2026) | DOI: https://doi.org/10.1056/NEJMoa1607141
• PMID 42029986 — "Persistence-Dependent Effectiveness of Tirzepatide on the Cardio-Metabolic-Kidney Syndrome Outcomes in Obesity: Real-World Evidence from the United Arab Emirates." (2026) | DOI: https://doi.org/10.1056/NEJMoa2107519
• PMID 42013545 — "Peroxiredoxin Ⅲ safeguards cardiac function against doxorubicin by regulating mitochondrial quality control via H2O2 detoxification." (2026) | DOI: https://doi.org/10.1089/ars.2012.4849
• PMID 42027914 — VIP cardiovascular and immunomodulatory research reference. | DOI: https://doi.org/10.1042/BST0331114
• PMID 41945630 — "Are serum MOTS-c levels and MOTS-c m.1382A>C polymorphism related to polycystic ovary syndrome?" (2026) | DOI: https://doi.org/10.1016/j.cmet.2015.01.013
• PMID 41975304 — "Preserving brain health in aging: structural and biochemical benefits of water based resistance training, a randomized controlled trial." (2026) | Humanin signaling reference. | DOI: https://doi.org/10.1073/pnas.101208398
• PMID 40465419 — "Identification of alexamorelin consumption biomarkers using human hepatocyte incubations and high-resolution mass spectrometry." (2025) | Hexarelin metabolic reference. | DOI: https://doi.org/10.1210/jcem.84.6.5815

For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.